The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N-((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
本公开涉及药用可接受的盐、共晶体及其结晶形式,其中一种化合物为N-((S)-1-(3-(4-
氯-3-(甲磺酰
氨基)-1-(
2,2,2-三氟乙基)-1H-
吲哚-7-基)-6-(3-甲基-3-(甲磺酰基)丁-1-炔-1-基)
吡啶-2-基)-2-(3,5-二
氟苯基)乙基)-2-((3bS,4aR)-5,5-二
氟-3-(三
氟甲基)-3b,4,4a,5-四氢-1H-环丙[3,4]环戊[1,2-c]
吡唑-1-基)乙酰胺,用于治疗逆转录病毒科病毒感染,包括由HIV病毒引起的感染。